Insider Buying: Knight Therapeutics Inc. (TSE:GUD) Insider Purchases 26,400 Shares of Stock

Knight Therapeutics Inc. (TSE:GUD) insider Sime Armoyan acquired 26,400 shares of the stock in a transaction that occurred on Friday, September 15th. The stock was acquired at an average cost of C$4.38 per share, for a total transaction of C$115,737.60.

Knight Therapeutics Price Performance

Shares of TSE GUD opened at C$4.43 on Tuesday. The stock has a market cap of C$472.99 million, a price-to-earnings ratio of -31.64, a PEG ratio of -1,013.50 and a beta of 0.48. Knight Therapeutics Inc. has a 52 week low of C$4.28 and a 52 week high of C$5.60. The company’s 50-day moving average price is C$4.68 and its 200 day moving average price is C$4.76. The company has a current ratio of 3.16, a quick ratio of 1.79 and a debt-to-equity ratio of 9.81.

Knight Therapeutics (TSE:GUD) last issued its quarterly earnings data on Thursday, August 10th. The company reported C$0.02 EPS for the quarter, missing analysts’ consensus estimates of C$0.03 by C($0.01). The business had revenue of C$89.91 million during the quarter, compared to analyst estimates of C$80.15 million. Knight Therapeutics had a negative net margin of 4.81% and a negative return on equity of 1.92%. As a group, research analysts forecast that Knight Therapeutics Inc. will post -0.07 earnings per share for the current fiscal year.

Knight Therapeutics Company Profile

Knight Therapeutics Inc develops, manufactures, acquires, in-licenses, out-licenses, markets, and distributes pharmaceutical and consumer health products, and medical devices worldwide. It offers Tafasitamab for relapsed or refractory diffuse large B-cell lymphoma; Pemigatinib for metastatic cholangiocarcinoma; Akynzeo for prevention of chemotherapy-induced acute and delayed nausea and vomiting; Aloxi for prevention of acute nausea and vomiting associated with emetogenic cancer chemotherapy; Fostamatinib for chronic immune thrombocytopenia; Nerlynx for extended adjuvant breast cancer and metastatic breast cancer; Trelstar for advanced prostate cancer; Vidaza for myelodysplastic syndrome; Abraxane for metastatic pancreatic cancer; Halaven for metastatic breast cancer and soft tissue sarcoma; and Lenvima for advanced renal cell cancer and for differentiated thyroid cancer and unresectable hepatocellular carcinoma.